Results 41 to 50 of about 56,171 (221)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. [PDF]

, 2014
BackgroundIn dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum.
Cartier, Anna, Desplats, Paula, Masliah, Eliezer, Overk, Cassia R, Patrick, Christina, Price, Diana L, Rockenstein, Edward, Shaked, Gideon, Spencer, Brian, Ubhi, Kiren   +9 more
core   +3 more sources

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy [PDF]

, 2015
BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission ...
Cam Donaldson, Christopher Davison, David Williams, Fahn, Jim Lloyd, John T. O'Brien, Karl Herholz, Kirsty Olsen, Michael J. Firbank, Nicky Barnett, Robert Barber, Roth, Schmidt, Sean J. Colloby   +13 more
core   +1 more source

Kinematic analysis of handwriting movements in patients with Alzheimer's disease, mild cognitive impairment, depression and healthy subjects [PDF]

, 2003
A variety of studies have demonstrated that motor disorders, parkinsonism and extrapyramidal motor symptoms (EPMS) are common in patients with Alzheimer's disease (AD).
Burger, K., Hampel, H., Hegerl, Ulrich, Mergl, R., Möller, Hans-Jürgen, Schroter, A.   +5 more
core   +1 more source

Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia

Alzheimer’s Research & Therapy, 2018
Background Dementia due to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common neurodegenerative causes of dementia. They commonly occur together, especially in older people, but clinical identification of these diseases ...
Alan J. Thomas, Fariba Mahin-Babaei, Mohammad Saidi, Debbie Lett, John Paul Taylor, Lauren Walker, Johannes Attems   +6 more
doaj   +1 more source

Whole-brain patterns of 1H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies [PDF]

, 2016
Acknowledgements We thank Craig Lambert for his help in processing the MRS data. The study was funded by the Sir Jules Thorn Charitable Trust (grant ref: 05/JTA) and was supported by the National Institute for Health Research (NIHR) Newcastle Biomedical ...
Blamire, A. M., Hayes, L., He, J., O'Brien, J. T., Su, L., Watson, R.   +5 more
core   +2 more sources

Parkinson's disease dementia: a neural networks perspective. [PDF]

, 2015
In the long-term, with progression of the illness, Parkinson's disease dementia affects up to 90% of patients with Parkinson's disease. With increasing life expectancy in western countries, Parkinson's disease dementia is set to become even more ...
Foltynie, T, Gratwicke, J, Jahanshahi, M
core   +1 more source

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. [PDF]

, 2019
Purpose of reviewThe aim of this study was to examine the synaptic biomarker neurogranin in cerebrospinal fluid (CSF) in different stages of HIV infection and in relation to what is known about CSF neurogranin in other neurodegenerative diseases.Recent ...
Blennow, Kaj, Fuchs, Dietmar, Gisslén, Magnus, Price, Richard W, Spudich, Serena, Yilmaz, Aylin, Zetterberg, Henrik   +6 more
core   +2 more sources

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football [PDF]

, 2017
IMPORTANCE: Players of American football may be at increased risk of long-term neurological conditions, particularly chronic traumatic encephalopathy (CTE).
Abdolmohammadi, Bobak, Alosco, Michael L., Alvarez, Victor E., Baugh, Christine M., Cantu, Robert C., Chaisson, Christine E., Cormier, Kerry A., Daneshvar, Daniel H., Goldstein, Lee E., Huber, Bertrand R., Katz, Douglas I., Kiernan, Patrick T., Kowall, Neil W., Kubilus, Caroline A., Martin, Brett M., McClean, Michael D., McHale, Lisa, McKee, Ann C., Mez, Jesse, Montenigro, Phillip H., Murphy, Lauren, Nowinski, Christopher J., Solomon, Todd M., Stein, Thor D., Stern, Robert A., Tripodis, Yorghos, Weuve, Jennifer   +26 more
core   +1 more source

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source